CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is -$1.71M, lower than 95% of all stocks globally
- PositionOperating margin is 1800.2%, higher than 95% of its Biotechnology peers (median -24.1%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
27.69BHKD3.53B · vs all stocks (USD)
Revenue (TTM)
-13.39MHKD-1.71M · vs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
-88.74%vs all stocks
Market Capitalization
27.69BHKD3.53B · vs all stocks (USD)
Enterprise Value
2.26BHKD287.46M · vs all stocks (USD)
Forward P/E
-30.64xvs Biotechnology peers
Price to Book (MRQ)
7.26xvs Biotechnology peers
Enterprise to Revenue
-168.43xvs Biotechnology peers
Enterprise to EBITDA
-6.11xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
1800.24%vs Biotechnology peers
Return on Assets (TTM)
-44.55%vs Biotechnology peers
Return on Equity (TTM)
-125.57%vs Biotechnology peers
Revenue (TTM)
-13.39MHKD-1.71M · vs all stocks (USD)
Revenue per Share (TTM)
-0.0300HKDUpdated Sep 20, 2026Gross Profit (TTM)
-13.39MHKD-1.71M · vs all stocks (USD)
EBITDA (TTM)
-368.96MHKD-47.03M · vs all stocks (USD)
Net Income (TTM)
-386.98MHKD-49.33M · vs all stocks (USD)
Operating Cash Flow (TTM)
-151.91MHKD-19.36M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-208.36MHKD-26.56M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00HKDUpdated Sep 20, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
102.00KCNYFY2025 · Dec 31, 2025Revenue
0.00CNYFY2025 · Dec 31, 2025Cost of Goods Sold
0.00CNYFY2025 · Dec 31, 2025Gross Profit
0.00CNYFY2025 · Dec 31, 2025Operating Income
-205.91MCNY-30.73M · vs all stocks (USD)
Pre-tax Income
-208.55MCNYFY2025 · Dec 31, 2025Income Tax Expense
0.00CNYFY2025 · Dec 31, 2025Net Income
-208.55MCNYFY2025 · Dec 31, 2025EBIT
-205.77MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-204.42MCNYFY2025 · Dec 31, 2025Research & Development
50.39MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
37.04MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
4.18MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.78MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.5500CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.5500CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
378.38MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
378.38MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-208.55MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
185.00KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-128.33MCNYFY2025 · Dec 31, 2025Free Cash Flow
-131.99MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
467.54MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-208.55MCNYFY2025 · Dec 31, 2025Stock-based Compensation
82.42MCNYFY2025 · Dec 31, 2025Other Non-cash Items
2.53MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-4.73MCNYFY2025 · Dec 31, 2025Capital Expenditures
-3.66MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00CNYFY2025 · Dec 31, 2025Purchase of Investments
-30.00MCNYFY2025 · Dec 31, 2025Sale of Investments
131.57MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
97.91MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-143.42MCNYFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-15.02MCNYFY2025 · Dec 31, 2025Other Financing Charges
-4.99MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
362.01MCNYFY2025 · Dec 31, 2025Shares Outstanding
391.09MSharesUpdated Sep 20, 2026Float Shares
151.53MSharesUpdated Sep 20, 2026% Held by Insiders
32.63%vs all stocks
% Held by Institutions
5.80%vs all stocks
Total Cash (MRQ)
477.97MHKD60.93M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.04HKDUpdated Sep 20, 2026Total Debt (MRQ)
178.51MHKD22.75M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.5720xvs Biotechnology peers
Current Ratio (MRQ)
2.56xvs Biotechnology peers
Book Value per Share (MRQ)
0.7977HKDUpdated Sep 20, 2026Total Assets
599.23MCNY89.42M · vs all stocks (USD)
Total Current Assets
556.28MCNYFY2025 · Dec 31, 2025Total Liabilities
150.64MCNYFY2025 · Dec 31, 2025Total Non-current Assets
42.95MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
9.59MCNYFY2025 · Dec 31, 2025Total Current Liabilities
141.06MCNYFY2025 · Dec 31, 2025Cash
467.54MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
467.54MCNYFY2025 · Dec 31, 2025Other Short-term Investments
54.47MCNYFY2025 · Dec 31, 2025Inventory
873.00KCNYFY2025 · Dec 31, 2025Accounts Payable
25.24MCNYFY2025 · Dec 31, 2025Short-term Debt
87.02MCNYFY2025 · Dec 31, 2025Long-term Debt
6.59MCNYFY2025 · Dec 31, 2025Common Stock (Book)
391.09MCNYFY2025 · Dec 31, 2025Retained Earnings
-1.34BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
448.59MCNY66.94M · vs all stocks (USD)
52-Week Low
4.94HKDUpdated Sep 20, 202652-Week High
77.00HKDUpdated Sep 20, 202652-Week Change
-88.74%vs all stocks
50-Day MA
6.03HKDUpdated Sep 20, 2026200-Day MA
34.67HKDUpdated Sep 20, 2026Avg 10-Day Volume
6.03MSharesUpdated Sep 20, 2026Avg 30-Day Volume
10.45MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
-0.6400HKDUpdated Sep 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 1800.2%, higher than 95% of its Biotechnology peers (median -24.1%)Significant
Operating margin: 18.00Industry median: -0.24Industry P95: 0.38Peers compared: 184
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is -$1.71M, lower than 95% of all stocks globallySignificant
Revenue (USD): -1,706,653Global P5: 35,820,060.775
Market cap is $3.53B, above the global median of $1.2BNotable
Market cap (USD): 3,529,938,681.895Global Median: 1,201,862,193
Companies that share the same coordination system — how they create, deliver, or capture value.
Hualan Biological Engineering Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ideaya Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tarsus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Xenon Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Acadia Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Livzon Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Organon & Co.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ambu A/S
Tier 1ProductionApproval-Gated PipelineRuleFlow
Laboratorios Farmacéuticos Rovi SA
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hubei Jumpcan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule